X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6297) 6297
Newsletter (273) 273
Newspaper Article (29) 29
Magazine Article (16) 16
Book Chapter (9) 9
Conference Proceeding (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5559) 5559
hiv infections - drug therapy (3563) 3563
female (2756) 2756
anti-hiv agents - therapeutic use (2689) 2689
male (2656) 2656
anti-hiv agents - pharmacokinetics (2488) 2488
pharmacology & pharmacy (2260) 2260
hiv (2246) 2246
adult (2210) 2210
anti-hiv agents - administration & dosage (1926) 1926
infectious diseases (1921) 1921
antiviral agents (1701) 1701
pharmacokinetics (1584) 1584
middle aged (1417) 1417
anti-hiv agents - adverse effects (1234) 1234
anti-hiv agents - pharmacology (1201) 1201
hiv-1 - drug effects (1153) 1153
animals (1112) 1112
immunology (1104) 1104
antiretroviral therapy (1094) 1094
anti-hiv agents (1005) 1005
hiv infection (999) 999
hiv infections - virology (952) 952
drug interactions (942) 942
drug therapy (919) 919
microbiology (899) 899
drug therapy, combination (892) 892
human immunodeficiency virus--hiv (891) 891
virology (812) 812
aids (772) 772
protease inhibitors (745) 745
human-immunodeficiency-virus (740) 740
viral load (717) 717
treatment outcome (697) 697
tenofovir (680) 680
antiretroviral drugs (657) 657
hiv-1 (648) 648
anti-hiv agents - blood (630) 630
health aspects (621) 621
highly active antiretroviral therapy (611) 611
infection (610) 610
therapy (602) 602
research (600) 600
adolescent (595) 595
efavirenz (555) 555
analysis (543) 543
young adult (534) 534
zidovudine (515) 515
reverse transcriptase inhibitors - therapeutic use (513) 513
ritonavir (503) 503
hiv infections - prevention & control (496) 496
hiv infections - complications (494) 494
pregnancy (482) 482
anti-hiv agents - chemistry (475) 475
cd4 lymphocyte count (475) 475
adenine - analogs & derivatives (464) 464
antiretroviral therapy, highly active (463) 463
reverse transcriptase inhibitors - pharmacokinetics (462) 462
safety (460) 460
nevirapine (457) 457
aids/hiv (444) 444
pharmacology (436) 436
virus diseases (436) 436
dosage and administration (435) 435
area under curve (428) 428
drugs (424) 424
prevention (400) 400
human immunodeficiency virus (399) 399
hiv infections - metabolism (397) 397
drug administration schedule (393) 393
in-vitro (382) 382
chemistry, medicinal (378) 378
child (377) 377
care and treatment (372) 372
rats (369) 369
aged (363) 363
dose-response relationship, drug (363) 363
hiv-1 - genetics (363) 363
drug resistance, viral (360) 360
immunodeficiency-virus type-1 (360) 360
hiv infections - blood (354) 354
acquired immune deficiency syndrome--aids (349) 349
hiv protease inhibitors - pharmacokinetics (349) 349
research article (345) 345
hiv patients (344) 344
hiv protease inhibitors - therapeutic use (340) 340
lamivudine (330) 330
ritonavir - administration & dosage (327) 327
efficacy (326) 326
reverse transcriptase inhibitors - administration & dosage (324) 324
ritonavir - pharmacokinetics (323) 323
drug resistance (320) 320
risk factors (318) 318
clinical trials (312) 312
emtricitabine (306) 306
ritonavir - therapeutic use (306) 306
administration, oral (304) 304
medicine & public health (301) 301
reverse-transcriptase inhibitors (297) 297
hiv infections - immunology (296) 296
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6530) 6530
Spanish (65) 65
German (35) 35
French (22) 22
Japanese (19) 19
Portuguese (13) 13
Dutch (5) 5
Italian (5) 5
Chinese (3) 3
Russian (2) 2
Czech (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 03/2010, Volume 87, Issue 3, pp. 322 - 329
Journal Article
PLoS medicine, ISSN 1549-1676, 2018, Volume 15, Issue 11, p. e1002690
...) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States... 
MEDICINE, GENERAL & INTERNAL | MEN | PREVENTION | ADULTS | RILPIVIRINE | PREEXPOSURE PROPHYLAXIS | PROTECTS MACAQUES | HIV Infections - prevention & control | United States | Humans | Middle Aged | Male | Pyridones - blood | Anti-HIV Agents - administration & dosage | Young Adult | Pyridones - administration & dosage | Malawi | HIV Infections - diagnosis | Brazil | Adult | Female | HIV Infections - transmission | Anti-HIV Agents - blood | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Risk Assessment | Anti-HIV Agents - adverse effects | HIV Infections - virology | Risk Factors | Treatment Outcome | Injections, Intramuscular | Anti-HIV Agents - pharmacokinetics | Adolescent | South Africa | Aged | Drug Monitoring | Delayed-Action Preparations | Pyridones - adverse effects | Prevention | Tenofovir | Usage | Safety and security measures | Analysis | Clinical trials | Pharmacokinetics | HIV infection | Drug delivery systems | Sexually transmitted diseases--STD | Funding | Risk | Population studies | Infections | Males | Randomization | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Safety | Supervision | Integrase | Medical research | Population characteristics | Health risks | Pharmacology | Injection | Medicine | Disease prevention | Infectious diseases | Men | Software | Females | Cancer | STD | Sexually transmitted diseases | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 04/2015, Volume 79, Issue 4, pp. 636 - 649
Journal Article
Journal of controlled release, ISSN 0168-3659, 04/2018, Volume 275, pp. 229 - 241
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 54, Issue 6, pp. 1114 - 1122
..., post-transplant HCV infection, hemodialysis patients, and others [3]. The HCV protease inhibitor BILN 2061 was the first agent in man to specifically target HCV... 
Gastroenterology and Hepatology | Antiviral | Resistant variants | Hepatitis C virus | Pegylated interferon | Ribavirin | PLUS RIBAVIRIN | BILN-2061 | TELAPREVIR | EFFICACY | VX-950 | HEPATITIS-C-VIRUS | IN-VITRO | EARLY ANTIVIRAL ACTIVITY | PEGINTERFERON ALPHA-2A | ATAZANAVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Male | Thiazoles - administration & dosage | Recombinant Proteins | Oligopeptides - adverse effects | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Protease Inhibitors - pharmacology | Hepatitis C - blood | Ribavirin - administration & dosage | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Hepacivirus - drug effects | Antiviral Agents - pharmacology | Double-Blind Method | Oligopeptides - pharmacokinetics | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Drug Resistance, Viral - genetics | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Hepatitis C - virology | Oligopeptides - administration & dosage | Thiazoles - pharmacology | Oligopeptides - pharmacology | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Antiviral agents | Care and treatment | Safety and security measures | Hotels and motels | Immunodeficiency | Aspartate | Biological response modifiers | HIV (Viruses) | Anti-HIV agents | Complications and side effects | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C | Viral Nonstructural Proteins | Oligopeptides | Polyethylene Glycols | Interferon-alpha | Protease Inhibitors | Drug Resistance, Viral | Antiviral Agents | Viral Load | Life Sciences | Thiazoles | Hepacivirus | Carrier Proteins | Cancer
Journal Article
Journal Article
HIV medicine, ISSN 1464-2662, 01/2018, Volume 19, Issue 1, pp. 1 - 6
Objectives The National Health Service in England (NHS England) does not provide pre‐exposure prophylaxis (PrEP) against HIV, forcing people to purchase... 
pre‐exposure prophylaxis | HIV infection | generic antiretroviral drugs | pre-exposure prophylaxis | INFECTIOUS DISEASES | HIV | ACCESS | HIV Infections - prevention & control | Pre-Exposure Prophylaxis - methods | Humans | Middle Aged | Male | Tenofovir - administration & dosage | Disease Transmission, Infectious - prevention & control | Anti-HIV Agents - administration & dosage | Young Adult | Emtricitabine - pharmacokinetics | Chromatography, Liquid | Adult | Female | Emtricitabine - administration & dosage | Emtricitabine - adverse effects | Tenofovir - adverse effects | Anti-HIV Agents - adverse effects | Treatment Outcome | Tenofovir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Plasma - chemistry | Adolescent | London | Aged | Chemoprevention - methods | Antiviral agents | Safety and security measures | Liquid chromatography | Marketing research | HIV (Viruses) | Highly active antiretroviral therapy | Generic drugs | Analysis | Internet | Hepatitis C virus | Hepatitis C | Health aspects | Formulations | Medical research | Renal function | Prophylaxis | Health risks | Clinical trials | Risk reduction | Viruses | Pharmacology | Exposure | Infections | Authenticity | Tenofovir | Hepatitis | Human immunodeficiency virus--HIV | In vivo methods and tests | Hepatitis B virus | Pharmacokinetics | Hepatitis B | Kidney transplantation
Journal Article